FLT4 and lung carcinoma: Kajita and colleagues were the first to report VEGFR-3 expression in lung cancer cells, but they did not evaluate its impact on the prognosis or the correlation of VEGFR-3 expression with clinicopathologic features in patients with NSCLC [44].